Full history for every metric is available with a Kvantra account
Key financial summary
Financials in EURTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 0.1 | 0.0 | 4.8 | 30.1 | -11.6 | 29.6 | - | 25.9 |
| Operating profit | €m | -10.8 | - | ||||||
| Net profit | €m | -33.6 | -47.0 | -57.0 | -39.7 | -68.1 | -24.0 | - | -26.9 |
| EPS reported | € | -0.51 | - | ||||||
| Operating cashflow per share | € | -0.70 | - | ||||||
| Capex per share | € | 0.01 | - | ||||||
| FCF per share | € | -0.72 | - | ||||||
| Free cash flow | €m | -34.0 | - | ||||||
| Net debt | €m | 39.5 | - | ||||||
| Book value equity | €m | -84.5 | - | ||||||
| Book value per share | € | -1.78 | - | ||||||
| Number of shares | m | 47.42 | - | ||||||
| DPS (TTM paid) | € | 0.00 | - |
Financial summary
Financials in EURTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -10.94 | - | ||||||
| P/S LTM | x | 31.19 | - | ||||||
| P/FCF LTM | x | -27.22 | - | ||||||
| EV/EBITDA LTM | x | -80.15 | - | ||||||
| EV/Sales LTM | x | 32.63 | - | ||||||
| Earnings Yield LTM | % | -2.59% | - | ||||||
| FCF Yield | % | -3.67% | - | ||||||
| Quality | |||||||||
| ROE | % | 28.36% | - | ||||||
| ROIC | % | -74.29% | - | ||||||
| Operating margin | % | -36.49% | - | ||||||
| Gross margin | % | 100.00% | - | ||||||
| FCF/Sales | % | -114.59% | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | - | ||||||
| Dividend Growth | % | 0.00% | - | ||||||
| Payout Ratio | % | 0.00% | - | ||||||
| FCF/Debt | x | -0.36 | - | ||||||
| Net Debt/EBITDA | x | -3.53 | - | ||||||
| EBIT/Net interest | x | -1.04 | - | ||||||
| Net debt/market cap | % | 4.27% | - | ||||||
| Net debt/Equity | x | -0.47 | - | ||||||
| Gross debt/equity | x | -1.13 | - | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Based on consensus from external analysts. Not Kvantra's opinion.
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free